Analyzing Myovant Sciences (MYOV) and The Competition
Myovant Sciences (NYSE: MYOV) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it compare to its rivals? We will compare Myovant Sciences to similar businesses based on the strength of its risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.
Volatility & Risk
Myovant Sciences has a beta of -2.42, meaning that its share price is 342% less volatile than the S&P 500. Comparatively, Myovant Sciences’ rivals have a beta of 1.03, meaning that their average share price is 3% more volatile than the S&P 500.
Valuation and Earnings
This table compares Myovant Sciences and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Myovant Sciences||N/A||-$83.44 million||-8.06|
|Myovant Sciences Competitors||$564.12 million||$96.17 million||44.55|
Myovant Sciences’ rivals have higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Myovant Sciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Myovant Sciences Competitors||-13,604.44%||-110.44%||-27.79%|
Institutional and Insider Ownership
79.2% of Myovant Sciences shares are held by institutional investors. Comparatively, 43.5% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 2.8% of Myovant Sciences shares are held by insiders. Comparatively, 15.4% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a summary of current ratings and target prices for Myovant Sciences and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Myovant Sciences Competitors||138||801||1767||59||2.63|
Myovant Sciences currently has a consensus price target of $22.50, indicating a potential upside of 97.89%. As a group, “Biopharmaceuticals” companies have a potential upside of 11.55%. Given Myovant Sciences’ stronger consensus rating and higher possible upside, research analysts clearly believe Myovant Sciences is more favorable than its rivals.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.